RADNOSTIX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RADNOSTIX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $10.37M | Mar 22, 2019 |
| FY2018 | Dec 31, 2017 | $7.42M | Mar 22, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.90M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $12.27M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $11.18M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.66M | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $9.36M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.96M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $10.37M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.42M | Mar 22, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.38M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $6.29M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $5.74M | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $5.46M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.67M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.69M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.24M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.84M | Mar 30, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($908.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($869.0K) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $303.2K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($902.3K) | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $2.20M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.52M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($844.6K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.76M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($1.88M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($956.2K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.9K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($776.3K) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($1.20M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($680.8K) | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | ($415.7K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($558.3K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($290.1K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.07M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($1.50M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $435.8K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $610.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $577.4K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $533.7K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $271.7K | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $219.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $263.4K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $468.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $376.7K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $511.3K | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $620.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $638.8K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $582.6K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($1.50M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($161.9K) | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $1.15M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($53.6K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $97.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($465.7K) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($324.2K) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $534.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $721.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $149.1K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $120.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $205.5K | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $7.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $208.1K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $86.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $110.1K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $93.6K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $17.16M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.91M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $16.24M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $16.33M | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $17.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.26M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.99M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $12.01M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $11.38M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.14M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.81M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $12.87M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $11.90M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $13.60M | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $14.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.37M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.84M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.66M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $9.62M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.69M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $4.04M | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $4.34M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | $2.73M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $573.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.19M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.60M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.23M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $1.71M | Mar 30, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.38M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.38M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.38M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.38M | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $1.38M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.38M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.38M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 30, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($128.23M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($127.32M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($127.33M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($126.46M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($126.76M) | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | ($125.86M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($128.06M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($126.54M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($125.70M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($121.94M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.95M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.69M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $2.38M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $474.9K | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | $1.11M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $575.4K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $828.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $409.3K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $314.5K | Mar 30, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.93M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $2.21M | Mar 4, 2025 |
| FY2023 | Dec 31, 2023 | $2.05M | Mar 29, 2024 |
| FY2022 | Dec 31, 2022 | $1.68M | Apr 6, 2023 |
| FY2021 | Dec 31, 2021 | $1.96M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $1.63M | Mar 30, 2021 |
| FY2019 | Dec 31, 2019 | $2.75M | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $655.1K | Mar 22, 2019 |
| FY2017 | Dec 31, 2017 | $515.7K | Mar 30, 2018 |
| FY2016 | Dec 31, 2016 | $3.97M | Mar 31, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 528.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 523.55M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 519.79M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 514.89M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 502.58M | Apr 6, 2023 |
| FY2021 | Dec 31, 2020 | 424.34M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 419.84M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 413.17M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 406.79M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 405.00M | Mar 30, 2018 |